Literature DB >> 16956446

Medical management of atrial fibrillation.

Ahmad Hersi1, D George Wyse.   

Abstract

Atrial fibrillation (AF) is the most common sustained tachyarrhythmia encountered in clinical practice. The management of AF remains associated with many challenges that make its treatment a vexing problem. However, in recent years extraordinary progress has been made in the understanding and management of AF. In general, antiarrhythmic drugs for rhythm control have been disappointing. We have a better understanding of pharmacologic cardioversion and this has led to newer strategies, such as intermittent therapy. Several studies have been completed comparing pharmacologic rhythm control with pharmacologic heart rate control. There is also an emerging body of evidence concerning the value of adjunctive drug use for rhythm control using drugs that would not usually be considered to be antiarrhythmic. Finally, antithrombotic therapy is an increasingly important part of the medical management of AF. This article summarizes the results of many of the recent publications and their clinical implications concerning management of this common rhythm disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956446     DOI: 10.1007/s11886-006-0070-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  23 in total

1.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

Review 2.  Rate control vs rhythm control strategies in atrial fibrillation.

Authors:  D George Wyse
Journal:  Prog Cardiovasc Dis       Date:  2005 Sep-Oct       Impact factor: 8.194

3.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

Review 4.  Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy.

Authors:  Hector F Lozano; Cesar A Conde; Todd Florin; Gervasio A Lamas
Journal:  Heart Rhythm       Date:  2005-09       Impact factor: 6.343

5.  Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.

Authors:  E L Pritchett; R L Page; S J Connolly; S R Marcello; D J Schnell; W E Wilkinson
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

Review 6.  Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.

Authors:  Joachim R Ehrlich; Stefan H Hohnloser; Stanley Nattel
Journal:  Eur Heart J       Date:  2005-11-25       Impact factor: 29.983

7.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Authors:  Gregory W Albers; Hans-Christoph Diener; Lars Frison; Margaretha Grind; Mark Nevinson; Stephen Partridge; Jonathan L Halperin; Jay Horrow; S Bertil Olsson; Palle Petersen; Alec Vahanian
Journal:  JAMA       Date:  2005-02-09       Impact factor: 56.272

8.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

9.  Rate control versus rhythm control--decision making.

Authors:  D G Wyse; Christopher S Simpson
Journal:  Can J Cardiol       Date:  2005-09       Impact factor: 5.223

10.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.

Authors:  Paolo Alboni; Giovanni L Botto; Nicola Baldi; Mario Luzi; Vitantonio Russo; Lorella Gianfranchi; Paola Marchi; Massimo Calzolari; Alberto Solano; Raffaele Baroffio; Germano Gaggioli
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

View more
  3 in total

Review 1.  Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes.

Authors:  T Jared Bunch; Bernard J Gersh
Journal:  J Gen Intern Med       Date:  2010-11-25       Impact factor: 5.128

2.  Patient perspectives of dabigatran: analysis of online discussion forums.

Authors:  Mary S Vaughan Sarrazin; Peter Cram; Alexandur Mazur; Melissa Ward; Heather Schacht Reisinger
Journal:  Patient       Date:  2014       Impact factor: 3.883

3.  Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.

Authors:  Soon Yong Suh; Woong Chol Kang; Pyung Chun Oh; Hanul Choi; Chan Il Moon; Kyounghoon Lee; Seung Hwan Han; Taehoon Ahn; In Suck Choi; Eak Kyun Shin
Journal:  Heart Vessels       Date:  2013-08-24       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.